{"name":"probeMap/hugo_gencode_good_hg19_V24lift37_probemap","type":"probeMap","version":"2017-07-25","assembly":"hg19","url":"http://hgdownload.cse.ucsc.edu/goldenPath/hg19/database/wgEncodeGencodeBasicV24lift37.txt.gz","wrangling_procedure":"convert UCSC GB download to start index 1","label":"HUGO: human gene symbol (hg19) e.g. TP53","userlevel":"basic","idtype":"gene"}

{"longTitle":"Normalized pooled gene expression data from multiple studies","cohort":"Breast Cancer (Yau 2010)","url":"http://www.ncbi.nlm.nih.gov/pubmed/20946665","probeMap":"probeMap/hugo_gencode_good_hg19_V24lift37_probemap","dataSubType":"gene expression","citation":"Breast Cancer Res. 2010 Oct 14;12(5):R85.","label":"Gene expression","author":"Yau C, Esserman L, Moore DH, Waldman F, Sninsky J, Benz CC.","articletitle":"A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer.","tags":["cancer"],"anatomical_origin":["Breast"],"name":"YauClinical_public/YauGeneExp_genomicMatrix","dataproducer":"Christina Yau, Laura Esserman, Dan H Moore, Fred Waldman, John Sninsky, Christopher C Benz","wrangling_procedure":"Data from Dr. Christina Yau at Buck Inst.  Dr. Yau integrated array data from four independent studies GSE2034, GSE5327, GSE7390, NKI295, array data is adjusted using DWD to minimize batch effect between the four different studies.","sample_type":["tumor"],"redistribution":true,"type":"genomicMatrix","wrangler":"Mia Grifford","version":"2011-11-01","gdata_tags":["transcription","mRNA"],"primary_disease":"breast cancer","pmid":"20946665","description":"A multigene HRneg/Tneg signature linked to immune/inflammatory cytokine regulation was identified from pooled expression microarray data and shown to be superior to other reported gene signatures in predicting the metastatic outcome of early stage and conservatively managed HRneg and Tneg breast cancer. Further validation of this prognostic signature may lead to new therapeutic insights and spare many newly diagnosed breast cancer patients the need for aggressive adjuvant chemotherapy."}